[go: up one dir, main page]

AU2001268661A1 - 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase - Google Patents

20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Info

Publication number
AU2001268661A1
AU2001268661A1 AU2001268661A AU6866101A AU2001268661A1 AU 2001268661 A1 AU2001268661 A1 AU 2001268661A1 AU 2001268661 A AU2001268661 A AU 2001268661A AU 6866101 A AU6866101 A AU 6866101A AU 2001268661 A1 AU2001268661 A1 AU 2001268661A1
Authority
AU
Australia
Prior art keywords
lyase
fluoro
inhibitors
alpha reductase
steroids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001268661A
Inventor
Joseph P. Burkhart
Cynthia A. Gates
Norton P. Peet
Philip M. Weintraub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc filed Critical Aventis Pharmaceuticals Inc
Publication of AU2001268661A1 publication Critical patent/AU2001268661A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
AU2001268661A 2000-06-27 2001-06-21 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase Abandoned AU2001268661A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21456100P 2000-06-27 2000-06-27
US60214561 2000-06-27
US29088101P 2001-05-14 2001-05-14
US60290881 2001-05-14
PCT/US2001/019889 WO2002000681A1 (en) 2000-06-27 2001-06-21 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Publications (1)

Publication Number Publication Date
AU2001268661A1 true AU2001268661A1 (en) 2002-01-08

Family

ID=26909117

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001268661A Abandoned AU2001268661A1 (en) 2000-06-27 2001-06-21 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase

Country Status (3)

Country Link
EP (1) EP1409512A1 (en)
AU (1) AU2001268661A1 (en)
WO (1) WO2002000681A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10043846A1 (en) * 2000-09-04 2002-04-04 Jenapharm Gmbh 17-methylene steroids, process for their preparation and pharmaceutical compositions containing them
DE10141984A1 (en) 2001-08-28 2003-03-20 Jenapharm Gmbh New 17-methylene-4-azasteroids
DE102006008074B4 (en) * 2006-02-22 2013-08-14 RUHR-UNIVERSITäT BOCHUM Treatment of cancer with olfactory receptor ligands
RU2009116632A (en) 2006-10-02 2010-11-10 Кортендо Инвест, Аб (Se) KETOCONAZOLE ENANTIOMER IN PEOPLE
GB201102913D0 (en) 2011-02-18 2011-04-06 Univ Birmingham Novel therapeutic

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3364238A (en) * 1966-04-04 1968-01-16 Searle & Co 3-oxygenated spiro[androstene-17, 1'-cycloprop-2'-ene], 2', 3'-dihydro derivatives corresponding and intermediates thereto
US5994334A (en) * 1997-02-05 1999-11-30 University Of Maryland Androgen synthesis inhibitors

Also Published As

Publication number Publication date
EP1409512A1 (en) 2004-04-21
WO2002000681A1 (en) 2002-01-03

Similar Documents

Publication Publication Date Title
AU2001262830A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160630A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
IL160648A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002234597A1 (en) Branched primary alcohol compositions and derivatives thereof
AU2001249670A1 (en) Substituted thiazoles and the use thereof as inhibitors of plasminogen activatorinhibitor-1
AU2002224079A1 (en) O/W emulsion composition and method of preparing the same
AU2520799A (en) Quantification by inhibition of amplification
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
AU2001245977A1 (en) Method and composition for preventing or reducing the symptoms of menopause
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
GB9827391D0 (en) Aldose reductase inhibitors and pharmaceutical compositions
AU2002327055A1 (en) Topical compositions and methods of application
AU2001271031A1 (en) Cosmetic compositions for reducing and method of using the same
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU4543699A (en) Multibinding inhibitors of hmg-coa reductase
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2001268661A1 (en) 20-fluoro-17(20)-vinyl steroids as inhibitors of c17-20-lyase and 5-alpha reductase
AU2001247196A1 (en) Methods and compositions for detection of disease
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
AU4440199A (en) Methods and compositions for inhibition of angiogenesis
AU2002303552A1 (en) Methods and compositions for prevention of angioproliferation
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU4980400A (en) Compositions and methods for detection of active proteases
HUP0303920A3 (en) Pharmaceutical compositions containing combinations of aldose reductase inhibitor pyridazinons and cyclooxygenase 2 inhibitors